Maria E. Katsarou, Hellinida Thomadaki, Nikos Katsaros, Andreas Scorilas
Effect of bleomycin and cisplatin on the expression profile of SRA1, a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells
Recently, a new member of the human SR (Ser/Arg-rich) superfamily of pre-mRNA splicing factors, SRA1 (SR-A1), has been discovered and cloned from members of our group, whose gene was found to be overexpessed in a series of human tumors. In the present study, we investigated the significance of the alterations at the mRNA expression levels of the SRA1 gene, after treatment of HL-60 human promyelocytic leukemia cells with the anticancer drugs cisplatin and bleomycin. The kinetics of apoptosis and cell toxicity were investigated by DNA laddering, the MTT and the trypan blue assays, respectively. Total RNA was extracted and cDNA was prepared by reverse transcription. The splicing-related genes SRA1 and SC35, as well as the apoptosis-related gene BCL2 (Bcl-2), were amplified by PCR using gene specific primers. The results showed that the mRNA levels of SR-A1 were up-regulated upon treatment with the antibiotic bleomycin, whereas they were down-regulated along treatment of HL-60 human promyelocytic leukemia cells with cisplatin. Our results support that mRNA expression analysis of SRA1 gene may serve as a new prospective molecular factor, playing an important role in chemotherapy outcome in human leukemia.
Biological Chemistry, Walter de Gruyter
Print ISSN: 1431-6730
Volume: 2007
Pages: -
Show full article (external site)
Show all available items of this journal
Search
